<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225353</url>
  </required_header>
  <id_info>
    <org_study_id>EC12012/10IEI-9339</org_study_id>
    <nct_id>NCT02225353</nct_id>
  </id_info>
  <brief_title>Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery</brief_title>
  <acronym>PCP002</acronym>
  <official_title>Exploratory Efficacy Study of a Cervical Pessary Sustained Release Progesterone for the Prevention of Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorios Andromaco S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized
      progesterone for the prevention of preterm delivery, established through spontaneous birth
      before gestation weeks 32 (31 6/7) and 34 (33 6/7), when the pessary is inserted during weeks
      16th and 24th and removed at 36 6/7 weeks in pregnant women at high risk of premature birth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2013</start_date>
  <completion_date type="Actual">March 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevention of preterm birth</measure>
    <time_frame>up to 36 weeks of gestational age</time_frame>
    <description>To assess the efficacy of Cerclage Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous parturition before gestation weeks 32 (31 6/7) and 34 (33 6/7), when the pessary is inserted between weeks 16 and 24 and removed at 36 6/7 weeks in pregnant women at high risk of premature delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>premature rupture of membranes</measure>
    <time_frame>up to 36 weeks of gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anatomical features (position and length) of the uterine cervix</measure>
    <time_frame>up to 36 weeks of gestational age</time_frame>
    <description>during pregnant controls will be assessed anatomical features (position and length) of the uterine cervix and will be compared between term and preterm births</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the acceptability and tolerance of use of the cerclage pessary</measure>
    <time_frame>up to 36 weeks of gestational age</time_frame>
    <description>A questionnaire will be used to compared acceptability &amp; tolerance in the insertion, during pregnancy and during the extraction of cerclage pessary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related with the use of the cerclage pessary</measure>
    <time_frame>up to 36 weeks of gestational age</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Premature Birth</condition>
  <condition>Fetal Membranes, Premature Rupture</condition>
  <arm_group>
    <arm_group_label>Progesterone Cervical Pessary 6.3 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 pregnant women with Progesterone Cervical Pessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone Cervical Pessary 7.7 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 pregnant women with Progesterone Cervical Pessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone 200 mg vaginal capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90 pregnant women using Progesterone 200 mg vaginal capsules daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Cervical Pessary</intervention_name>
    <description>Progesterone Cervical Pessary: 6.3 g Progesterone Cervical Pessary: 7.7 g</description>
    <arm_group_label>Progesterone Cervical Pessary 6.3 g</arm_group_label>
    <arm_group_label>Progesterone Cervical Pessary 7.7 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 200 mg vaginal capsules</intervention_name>
    <description>Progesterone 200 mg vaginal capsules daily</description>
    <arm_group_label>Progesterone 200 mg vaginal capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a singleton intrauterine pregnancy, with 10-25 mm cervical length between
             gestation weeks 16 and 24, with no prior risk factors.

          -  Women with a singleton intrauterine pregnancy with 10 mm or more cervical length
             between 16 and 24 weeks of gestation, with prior risk factors:

          -  Prior history of preterm delivery before gestation week 35

          -  Prior history of premature rupture of membranes before gestation week 35

        Exclusion Criteria:

          -  Pregnancies with:

               -  Major fetal abnormalities, such as lethal malformations or defects requiring pre
                  or postnatal surgery; and fetal death before randomization.

               -  Prior history of premature rupture of membranes or prophylactic cervical cerclage
                  before study entry.

          -  Cervical and/or vaginal injuries prior to pessary insertion (e.g., cervical erosion
             secondary to trauma, infection, or cancer; vesico-vaginal or recto-vaginal fistulas).

          -  Unconscious, severely ill or mentally disabled women, or women 16 years of age or
             younger
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Grünenthal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de Chile, Hospital Barros Luco</name>
      <address>
        <city>Santiago</city>
        <state>International</state>
        <zip>7501257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Dr. Sótero del Río (CASR)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Alto Riesgo Obstétrico y Medicina Perinatal y en el Centro Perinatal Oriente (CERPO), Hospital Santiago Oriente, Dr. Luis Tisné Brousse</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Chile, Hospital Clínico San Borja Arriarán</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Dodd JM, Crowther CA, Cincotta R, Flenady V, Robinson JS. Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2005 Jun;84(6):526-33. Review.</citation>
    <PMID>15901258</PMID>
  </reference>
  <reference>
    <citation>Berghella V. Novel developments on cervical length screening and progesterone for preventing preterm birth. BJOG. 2009 Jan;116(2):182-7. doi: 10.1111/j.1471-0528.2008.02008.x. Review.</citation>
    <PMID>19076950</PMID>
  </reference>
  <reference>
    <citation>Jayasooriya GS, Lamont RF. The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth. Expert Opin Pharmacother. 2009 Apr;10(6):1007-16. doi: 10.1517/14656560902851403 . Review.</citation>
    <PMID>19351272</PMID>
  </reference>
  <reference>
    <citation>Newcomer J. Pessaries for the treatment of incompetent cervix and premature delivery. Obstet Gynecol Surv. 2000 Jul;55(7):443-8. Review.</citation>
    <PMID>10885649</PMID>
  </reference>
  <reference>
    <citation>Arabin B, Halbesma JR, Vork F, Hübener M, van Eyck J. Is treatment with vaginal pessaries an option in patients with a sonographically detected short cervix? J Perinat Med. 2003;31(2):122-33.</citation>
    <PMID>12747228</PMID>
  </reference>
  <reference>
    <citation>Goya M, Pratcorona L, Merced C, Rodó C, Valle L, Romero A, Juan M, Rodríguez A, Muñoz B, Santacruz B, Bello-Muñoz JC, Llurba E, Higueras T, Cabero L, Carreras E; Pesario Cervical para Evitar Prematuridad (PECEP) Trial Group. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet. 2012 May 12;379(9828):1800-6. doi: 10.1016/S0140-6736(12)60030-0. Epub 2012 Apr 3. Erratum in: Lancet. 2012 May 12;379(9828):1790.</citation>
    <PMID>22475493</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Pessaries</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

